Global Pomalidomide Market is segmented, by Dosage Forms & Strengths into 1mg, 2mg, 3mg, and 4mg. Pomalidomide is a small molecule analog of thalidomide under growth with Celgene company for the oral treatment of hematological and connective tissue diseases. Pomalidomide has effectiveness and safety of pomalidomide as monotherapy in patients with deteriorated and refractory manifold myeloma has also been evaluated in a phase 3 trails.Pomalidomide (also termed as 3-amino-thalidomide) is a derivative of thalidomide marketed by Celgene. It is anti-angiogenic and acts as an immunomodulator. Pomalidomide was acknowledged in February 2013 by the U.S. Food and Drug Administration (FDA) as a treatment for refractory and relapsed multiple myeloma.
Browse Details of Pomalidomide
Market at : https://www.millioninsights.com/industry-reports/pomalidomide-market
Pomalidomide Market is segmented,
by Clinical Trialsinto Phase I and Phase II. Phase I trial result showed
tolerable side effects, Phase II clinical trials for multiple myeloma and
myelofibrosis reported promising results, Phase III results showed significant
extension of progression-free survival, and overall survival in patients taking
pomalidomide and dexamethasone vs. dexamethasone alone.
Pomalidomide could also be
prescribed for patients with amyloidosis, prostate cancer, small cell lung
cancer, pancreatic cancer, graft-versus-host disease, and Wald Enstrom’s
macroglobulinemia.It has been acknowledged for use in people who have
conservative at least two prior treatments including lenalidomide and
bortezomib and have established disease progression on or within 60 days of
completion of the last therapy.Pomalidomide conventional inhibits myeloma cell
growth and angiogenesis. Up regulation of interferon gamma, IL-2 and IL-10 as
well as downregulation of IL-6 have been labeled for pomalidomide. These
changes may contribute to pomalidomide's anti-angiogenic and anti-myeloma
activities.
Research has proven that the
combination of pomalidomide (Pomalyst®) and low-dose dexamethasone may be
advantageous for some patients with multiple myeloma that has worsened
(progressed) despite other treatments. Patients who received the combination
therapy lived longer without the disease progressing (progression-free
survival) than patients who received high-dose dexamethasone alone. Overall
survival also improved in the group that received the combination therapy as
compared to the other group. Pomalidomide Market is segmented, by Geographical
Region into North America, China, Europe, Japan, and Southeast Asia, India.
Pomalidomide Market key players include Pfizer Allergan, Alnylam
Pharmaceuticals, Amgen, Angstrom Pharmaceuticals, Acceleron Pharma, Biocon,
Bionomicsand CASI Pharmaceuticals.
Get Sample Copy of
Pomalidomide Market at : https://www.millioninsights.com/industry-reports/pomalidomide-market/request-sample
No comments:
Post a Comment